We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Mild Brain Trauma Diagnosed with POC Device

By LabMedica International staff writers
Posted on 14 Aug 2018
Print article
Image: One drop of blood is enough for TBIcheck to diagnose a possible mild brain trauma. If a line appears below the control line, the injured person will have to go to the hospital for a CT scan (Photo courtesy of the University of Geneva).
Image: One drop of blood is enough for TBIcheck to diagnose a possible mild brain trauma. If a line appears below the control line, the injured person will have to go to the hospital for a CT scan (Photo courtesy of the University of Geneva).
Every year in Europe, three million people are admitted into hospitals for suspected mild traumatic brain injury (mTBI) cases. Biomarkers have been intensively studied for their potential as diagnostic tools in cases of mTBI to allow accurate diagnosis, improve patient management speeds and reduce medical costs.

Falling whilst skiing, tumbling down the stairs or getting hit on the head can cause symptoms such as blurred vision, vomiting, loss of consciousness or memory for about 30 minutes. There is then a risk of mild cerebral trauma, which represents more than 90% of brain injuries admitted to hospitals. Today, the only reliable diagnosis is the computerized tomography (CT) scan, which is only available in some hospitals and exposes patients to radiation.

An international team of scientists collaborating with University of Geneva (Geneva, Switzerland) recruited patients from three different European sites: Geneva, Seville and Barcelona. Cohort 1 included 132 patients, of whom 21 were CT-positive (16%). Independent Cohort 2 was used for panel validation on 109 patients, of whom 17 (16%) were CT-positive.

The team evaluated 13 proteins individually for their capacity to differentiate between patients with and without a brain lesion according to CT results. They gradually isolated four molecules indicating the presence of a brain injury: Heart-type fatty acid binding protein (H-FABP), Interleukin-10, S100 calcium-binding protein B (S100B) and Glial fibrillary acidic protein (GFAP). The team noticed that the H-FABP level alone makes it possible to confirm that there is no risk of trauma in one third of patients admitted after a shock.

The team developed a small device, a Point-of-Care Test (POCT) that analyses the level of proteins in the blood and allows, using a single drop of blood, to diagnose the possibility of a mild traumatic brain injury. The rapid diagnostic POCT test, called TBIcheck, was inspired by the principle of pregnancy testing: by placing a single drop of blood on the well of a small 5 cm plastic case, the patient knows within 10 minutes whether there is a risk of mild trauma, namely whether or not his H-FABP level is higher than 2.5 ng/mL of blood. In case of doubt when reading the result, a small reader, the Cube Reader, can be installed on TBIcheck. It will display the word "positive" or "negative" and send the result to the patient's or caregiver's smartphone via Bluetooth. The TBIcheck will be marketed from 2019 by Advanced Brain Companion Diagnostics (ABCDx, Geneva, Switzerland).

Jean-Charles Sanchez, PhD, a professor and senior study author, said, “Our study shows that the results are even more accurate when we combine H-FABP and GFAP levels. We are currently preparing an even more effective TBIcheck, which will allow 50% of patients to be sent home, but which requires an increase in the sensitivity of the test that receives the blood.” The underlying study was published on July 9, 2018, in the journal PLOS ONE.

Related Links:
University of Geneva
Advanced Brain Companion Diagnostics

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.